ASCO26: Bispecific antibody and RET fusion-targeting assets garner attention in NSCLC - Pharmaceutical Technology

While Summit’s Harmoni-6 results drew a mixed reaction, Eli Lilly’s positive Retvemo data was expanded its potential in adjuvant NSCLC. While Summit’s Harmoni-6 results drew a mixed reaction, Eli Lilly’s positive Retvemo data was expanded its potential in adjuvant NSCLC. First-line non-small cell lung cancer (NSCLC )is a highly competitive disease setting, and near-term readouts across several programs will shape the NSCLC treatment landscape. Image credit: [Near D Krasaesom]/Shutterstock.com Several abstracts and data presentations on emerging clinical research in non-small cell lung cancer prompted expert interest and discussion at the American Society of Clinical Oncology (ASCO) 2026, held 29 May–2…

Source: Pharmaceutical Technology